• Aged 18 to 70 years;

• Diagnosis of HCC with BCLC stage B/C;

• Anticipated survival time is longer than 3 months;

• Liver function grade Child-Pugh A or B, without hepatic encephalopathy;

• Left ventricular ejection fraction (LVEF) ≥ 50%;

• ECOG physical status 0-2;

• Laboratory tests at baseline meet the following: Absolute neutrophil count \>1.0 x 109/L; Absolute neutrophil count \>1.0 x 109/L; White blood cell count \> 2.0 x 109/L; Platelet count \> 60 x 109/L; Hgb \> 8.0 g/dL; ALT and AST ≤ 5 times the upper limit of normal (ULN), Serum total bilirubin (TBiL) ≤ 51 mmol/L, or \< 3 times the ULN.

• Female subjects of childbearing potential must take acceptable measures to minimize the likelihood of pregnancy during the trial. Female subjects of childbearing potential must have a negative serum or urine pregnancy result within 48 hours prior to treatment;

• Able to receive treatment and follow-up, including the need for the subject to receive treatment at the enrollment center.